Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Genmab A s
Genmab A s_20100114
Genmab A s_20100121
  

Genmab A s patents

Recent patent applications related to Genmab A s. Genmab A s is listed as an Agent/Assignee. Note: Genmab A s may have other listings under different names/spellings. We're not affiliated with Genmab A s, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Genmab A s-related inventors




Date Genmab A s patents (updated weekly) - BOOKMARK this page
08/24/17Human monoclonal antibodies against cd25
08/17/17Heterodimeric antibody fc-containing proteins and methods for production thereof
06/22/17Human antibodies and antibody-drug conjugates against cd74
06/08/17Antibodies binding axl
05/18/17Human antibody drug conjugates against tissue factor
02/09/17Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
02/02/17Stable igg4 antibodies
11/17/16Humanized or chimeric cd3 antibodies
09/29/16Antibody-drug conjugate lyophilised formulation
08/18/16Antibodies against human cd38
06/16/16Humanized or chimeric cd3 antibodies
06/09/16Bispecific antibodies and methods for production thereof
05/12/16Antibodies against cd38 for treatment of multiple myeloma
03/10/16Human antibody drug conjugates against tissue factor
02/25/16Human antibodies against tissue factor and methods of use thereof
02/18/16Heterodimeric antibody fc-containing proteins and methods for production thereof
12/31/15Antibody variants having modifications in the constant region
12/24/15Antibody variants having modifications in the constant region
11/19/15Monoclonal antibodies against c-met
09/17/15Human monoclonal antibodies against cd25
08/20/15Combination treatment of cd38-expressing tumors
01/01/15Monoclonal antibodies against cd32b
11/27/14Novel methods and antibodies for treating cancer
10/09/14Production of heterodimeric proteins
09/18/14Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
06/19/14Bispecific antibodies against her2
06/19/14Bispecific antibodies against her2 and cd3
06/19/14Human monoclonal antibodies against interleukin 8 (il-8)
05/22/14Human monoclonal antibodies to epidermal growth factor receptor (egfr)
04/03/14Human monoclonal antibodies against cd20
01/30/14Human antibodies and antibody-drug conjugates against cd74
12/26/13Stable igg4 antibodies
08/22/13Monoclonal antibodies against c-met
08/15/13Antibodies against human cd38
07/25/13Monoclonal antibodies against her2
07/04/13Monoclonal antibodies against her2 epitope
04/25/13Human antibody drug conjugates against tissue factor
04/18/13Novel methods for treating egfr-associated tumors
02/14/13Heterodimeric antibody fc-containing proteins and methods for production thereof
09/27/12Human monoclonal antibodies against cd25
06/28/12Human monoclonal antibodies against interleukin 8 (il-8)
01/26/12Methods for producing mixtures of antibodies
12/08/11Human antibodies against tissue factor
10/20/11Novel methods and antibodies for treating cancer
04/28/11Antibodies against cd38 for treatment of multiple myeloma
04/21/11Novel antibody therapies
04/21/11Compositions and methods for diagnosing and treating diabetic micro vascular complications
04/14/11Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
02/24/11Fusion or linked proteins with extended half life
02/17/11Monoclonal antibodies against cd32b
12/23/10Novel methods for treating egfr-associated tumors
12/23/10Non-glycosylated recombinant monovalent antibodies
12/02/10Human monoclonal antibodies against interleukin 8 (il-8)
12/02/10Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
11/18/10Method for extending the half-life of exogenous or endogenous soluble molecules
10/21/10Stable igg4 antibodies
10/07/10Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
06/17/10Prevention of rash in patients undergoing anti-egfr therapy
04/29/10Bispecific antibodies and methods for production thereof
04/15/10Combination treatment of cd38-expressing tumors
02/18/10High throughput methods for characterization of antibodies
01/21/10Therapy with cd4 binding peptides and radiation
01/21/10Potency assays for antibody drug substance binding to an fc receptor
01/14/10Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/24/09Use of effector-function-deficient antibodies for treatment of auto-immune diseases
Patent Packs
09/10/09Recombinant monovalent antibodies and methods for production thereof
06/18/09Methods for treating disorders involving monocytes
06/11/09Antibodies against cd38 for treatment of multiple myeloma
05/07/09Non-human mammalian arthritis model featuring human antibodies against citrul-linated proteins
03/26/09Human monoclonal antibodies against cd25
01/21/10Potency assays for antibody drug substance binding to an fc receptor
01/14/10Human monoclonal antibodies to epidermal growth factor receptor (egfr)







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Genmab A s in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Genmab A s with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';